EGFR and non-small cell lung carcinoma: However, another trial targeting Asian patients with EGFR-WT non-squamous NSCLC was prematurely terminated due to the increased incidence of interstitial lung disease in patient group treated with erlotinib and tivantinib, although preliminary data revealed that the PFS was longer in that group [20].